within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BX02_Gedocarnil;

model Gedocarnil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.35,
    Cl = 6.805555555555556e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0055,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011666666666666665,
    Tlag = 600,
    Vdp = 0.0025,
    k12 = 3.5e-06,
    k21 = 3.5e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Gedocarnil</td></tr><tr><td>ATC code:</td><td>N05BX02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.35</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Gedocarnil is an antipsychotic drug belonging to the benzamide class. It was investigated for the treatment of schizophrenia and other psychotic disorders but is not currently approved or marketed for therapeutic use.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies with reported parameters found for gedocarnil in the literature as of June 2024. All values below are estimates based on similar atypical antipsychotic agents.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05BX02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Gedocarnil;
